Group 1 - The total salary scale of CFOs in A-share listed companies reached 4.27 billion yuan in 2024 [1] - Among the CFOs in the pharmaceutical raw material sector, the average annual salary is 661,200 yuan [1] - The top three highest-paid CFOs are from Guobang Pharmaceutical, Zhejiang Pharmaceutical, and Xinhua Pharmaceutical, with salaries of 1.93 million yuan, 1.84 million yuan, and 1.57 million yuan respectively [1] Group 2 - The age distribution of CFOs shows that those aged 40-50 make up 36%, while those over 60 account for 5% [1] - The educational background of CFOs indicates that 65% hold a bachelor's degree, and only 2% have a high school education [1] - The salary distribution reveals that 44% of CFOs earn below 500,000 yuan, and another 44% earn between 500,000 and 1 million yuan [1] Group 3 - The largest salary decrease was observed for Liu Qingke from Huangshan Capsule, with a year-on-year decline of 19.04% [1] - The highest salary increase was recorded for Qian Dan from Nengte Technology, with a year-on-year increase of 100.58% [1]

Core Insights - The report highlights the importance of CFOs in listed companies, with the total salary scale for CFOs in A-share companies reaching 4.27 billion yuan in 2024 [1] - The average annual salary for CFOs in the raw material pharmaceutical sector is 661,200 yuan [1] Salary Distribution - The top three highest-paid CFOs are Gong Yuda from Guobang Pharmaceutical with 1.93 million yuan, Li Qirong from Zhejiang Pharmaceutical with 1.84 million yuan, and Hou Ning from Xinhua Pharmaceutical with 1.57 million yuan [1] - The salary distribution shows that 44% of CFOs earn below 500,000 yuan, 44% earn between 500,000 and 1 million yuan, and 12% earn above 1 million yuan [1] Age and Education Distribution - CFOs aged 40-50 constitute the majority at 36%, while those aged 60 and above account for 5% [1] - The educational background of CFOs shows that 65% hold a bachelor's degree, 21% have a master's degree, and only 2% have a high school diploma [1] Salary Changes - Liu Qingke from Huangshan Capsule experienced the largest salary decrease at 19.04%, while Qian Dan from Nengte Technology saw the highest salary increase at 100.58% [1]

Group 1 - The total salary scale of CFOs in A-share listed companies reached 4.27 billion yuan in 2024, with an average annual salary of 814,800 yuan [1] - Among the CFOs, those aged 40-50 represent the majority at 36%, while those aged 60 and above account for 5% [1] - The youngest CFO currently in office is 33 years old, from XinNuoWei, named Dai Long [1] Group 2 - The average annual salary of CFOs in the A-share raw material pharmaceutical companies is 661,200 yuan [2] - The salary distribution shows that 44% of CFOs earn below 500,000 yuan, while another 44% earn between 500,000 and 1 million yuan, and 12% earn above 1 million yuan [2] - The top three highest-paid CFOs are Gong Yuda from Guobang Pharmaceutical at 1.93 million yuan, Li Qirong from Zhejiang Pharmaceutical at 1.84 million yuan, and Hou Ning from Xinhua Pharmaceutical at 1.57 million yuan [2]

专题：专题|2024年度A股CFO数据报告：美的集团钟铮年薪946万，比亚迪周亚琳896万 作为上市公司核心管理层关键成员，财务总监CFO的地位与作用至关重要。新浪财经《2024年度A股 CFO数据报告》显示，2024年A股上市公司财务总监CFO群体薪酬规模合计达42.70亿元，平均年薪为 81.48万元。 其中，年薪排行前三的CFO分别为国邦医药的龚裕达、浙江医药的李齐融、新华制药的侯宁，三人年薪 分别为193.09万元、184.18 万元、156.7万元。 从薪酬变动幅度看（仅统计任职两年以上CFO薪资数据），黄山胶囊的刘清科2024年薪酬降幅最大，同 比降幅达19.04%；能特科技的蹇丹薪酬增幅最大，同比涨幅达100.58%。 分行业来看，统计数据显示，剔除2024年时任CFO已离任的公司后，A股共有43家上市原料药公司，其 聘任总体情况如下（部分统计口径剔除无效数据）。 责任编辑：公司观察 从CFO的年龄分布来看，40岁-50岁CFO是市场的中坚力量，占比共计达到36%；60岁以上的CFO占比 为5%；50岁-60岁的CFO群体占比为33%；40岁及以下CFO群体占比为26%。其中，目前仍任职的最年 ...

Core Viewpoint - The company is committed to a global market layout strategy, with its raw material products already being sold in the United States, although their contribution to overall revenue is currently low [1]. Group 1 - The company aims to enhance its competitiveness in the global pharmaceutical supply chain through continuous accumulation in R&D collaboration, lean production, and quality management systems [1]. - The company is steadily advancing its international business expansion [1].

（记者 张明双） 每经AI快讯，有投资者在投资者互动平台提问：董秘你好，请问咱们公司产品卖往美国的多吗？美国 现在要求他们药企巨头全部降低药价，这是不是意味着他们向我们这边性价比高的原料和研发服务有可 能加大比例？ 海森药业（001367.SZ）8月5日在投资者互动平台表示，公司坚持全球化市场布局战略，原料药产品已 有销往美国，但现阶段其对整体营收的贡献程度相对较低。公司将依托自身在研发协同、精益生产及质 量管理体系的持续积累，提升在全球医药产业链中的竞争力，稳步推进业务的国际化拓展。 ...

海森药业今日上涨4.79%，全天换手率31.12%，成交额3.19亿元，振幅8.83%。龙虎榜数据显示，机构净 买入1065.42万元，营业部席位合计净买入1850.98万元。 海森药业8月4日交易公开信息 | 买/卖 | 会员营业部名称 | 买入金额（万元） | 卖出金额（万元） | | --- | --- | --- | --- | | 买一 | 方正证券股份有限公司浙江分公司 | 2662.56 | 13.29 | | 买二 | 机构专用 | 1343.88 | 522.30 | | 买三 | 机构专用 | 812.03 | 364.13 | | 买四 | 机构专用 | 764.25 | 451.70 | | 买五 | 机构专用 | 674.26 | 541.65 | | 卖一 | 机构专用 | 216.53 | 865.75 | | 卖二 | 光大证券股份有限公司广州马场路证券营业部 | 1.05 | 702.50 | | 卖三 | 机构专用 | 674.26 | 541.65 | | 卖四 | 机构专用 | 1343.88 | 522.30 | | 卖五 | 麦高证券有限责任公司北京分公司 | 39 ...

资金流向方面，今日该股主力资金净流出1505.25万元，其中，特大单净流出787.77万元，大单资金净流 出717.48万元。近5日主力资金净流入2900.88万元。（数据宝） 海森药业8月1日交易公开信息 | 买/ | 会员营业部名称 | 买入金额（万 | 卖出金额（万 | | --- | --- | --- | --- | | 卖 | | 元） | 元） | | 买一 | 机构专用 | 864.43 | 196.83 | | 买二 | 麦高证券有限责任公司北京分公司 | 691.82 | 268.60 | | 买三 | 机构专用 | 546.52 | 92.82 | | 买四 | 机构专用 | 544.84 | 114.09 | | 买五 | 机构专用 | 542.11 | 0.00 | | 卖一 | 中信证券股份有限公司浙江分公司 | 139.48 | 1359.94 | | 卖二 | 中信证券股份有限公司福州湖东路证券营业部 | 1.09 | 728.93 | | 卖三 | 国泰海通证券股份有限公司上海长宁区江苏路证券营业 | 15.80 | 443.88 | | | 部 | | | | 卖四 | 东 ...

海森药业今日上涨3.71%，全天换手率35.09%，成交额3.57亿元，振幅10.24%。龙虎榜数据显示，机构净卖出1332.99万元，营业部席位合计净买入2275.09万元。 深交所公开信息显示，当日该股因日换手率达35.09%上榜，机构专用席位净卖出1332.99万元。 证券时报•数据宝统计显示，上榜的前五大买卖营业部合计成交6938.49万元，其中，买入成交额为3940.30万元，卖出成交额为2998.19万元，合计净买入942.10万元。 具体来看，今日上榜的营业部中，共有3家机构专用席位现身，即卖二、卖三、卖四，合计买入金额288.49万元，卖出金额1621.48万元，合计净卖出1332.99万元。 资金流向方面，今日该股主力资金净流入2609.13万元，其中，特大单净流入532.17万元，大单资金净流入2076.96万元。近5日主力资金净流入6135.88万元。（数据宝） 海森药业7月31日交易公开信息 ...

Group 1 - Haisen Pharmaceutical's stock rose by 3.71% with a turnover rate of 35.09% and a trading volume of 357 million yuan, showing a volatility of 10.24% [2] - Institutional investors net sold 13.33 million yuan, while brokerage seats collectively net bought 22.75 million yuan [2] - The stock was listed on the Shenzhen Stock Exchange due to its high turnover rate, with institutional proprietary seats net selling 13.33 million yuan [2] Group 2 - The top five brokerage seats accounted for a total transaction volume of 69.38 million yuan, with a buying amount of 39.40 million yuan and a selling amount of 29.98 million yuan, resulting in a net buying of 9.42 million yuan [2] - Among the brokerage seats, three institutional proprietary seats were involved, with a total buying amount of 2.88 million yuan and a selling amount of 16.21 million yuan, leading to a net sell of 13.33 million yuan [2] - The stock experienced a net inflow of 26.09 million yuan from main funds today, including a net inflow of 5.32 million yuan from large orders and 20.77 million yuan from major funds, with a total net inflow of 61.36 million yuan over the past five days [2]